Xcovery edges closer to FDA approval for NSCLC ALK inhibitor
The new drug application included data from the Phase III eXalt3 study, published in JAMA Oncology in September 2021.
The new drug application included data from the Phase III eXalt3 study, published in JAMA Oncology in September 2021.
What's Your Reaction?
